Mycosis Fungoides

Topical hypericin showed efficacy in treating mycosis fungoides without significant skin absorption or significant cardiac changes, according to a study.

In patients with atopic dermatitis treated with dupilumab, a reversible and most likely benign lymphoid reaction could occur, according to a study.

In this edition, nearly $1 million in grants to aid diversity, equity, inclusion research; topical halcinonide may benefit patients with psoriasis; Asian patients may experience earlier mycosis fungoides diagnosis and more.

Asian patients are often diagnosed with mycosis fungoides at a younger age compared with other races and therefore may have higher overall survival rates, according to a study.

Topical synthetic hypericin ointment, activated with visible light, shows efficacy in reducing mycosis fungoides-cutaneous T-cell lymphoma lesions, according to a phase 3 study.

A post-hoc analysis of a key data set for chlormethine in mycosis fungoides showed that the gel formulation of the drug may be safer and more effective than the ointment, according to study findings.

Chlormethine gel showed efficacy in combination with corticosteroids or other treatments such as phototherapy in a cohort of patients with mycosis fungoides cutaneous T-cell lymphoma, according to the PROVe study.

Treatment with synthetic hypericin produced significant index lesion response in patients with early-stage mycosis fungoides cutaneous T-cell lymphoma, according to a study presented at AAD VMX 2021.

Cutaneous staging was the only significant predictive variable of disease-specific survival in patients with folliculotropic mycosis fungoides, according to a study published in JAMA Dermatology.

The combination of mogamulizumab and topical steroids conferred favorable outcomes to patients with previously treated cutaneous T-cell lymphoma, according to study results presented at Society of Hematologic Oncology Annual Meeting.